



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Percutaneous Balloon Kyphoplasty, Radiofrequency Kyphoplasty, and Mechanical Vertebral Augmentation

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 485

BCBSA Reference Number: 6.01.38 (For Plan internal use only)

Related Policies

Percutaneous Vertebroplasty and Sacroplasty, #[484](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Balloon kyphoplasty may be considered **MEDICALLY NECESSARY** for the treatment of symptomatic thoracolumbar osteoporotic vertebral compression fractures that have failed to respond to conservative treatment (eg, analgesics, physical therapy, rest) for at least 6 weeks.

Mechanical vertebral augmentation with an FDA cleared device may be considered **MEDICALLY NECESSARY** for the treatment of symptomatic thoracolumbar osteoporotic vertebral compression fractures that have failed to respond to conservative treatment (eg, analgesics, physical therapy, rest) for at least 6 weeks.

Balloon kyphoplasty may be considered **MEDICALLY NECESSARY** for the treatment of severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies.

Mechanical vertebral augmentation with an FDA cleared device may be considered **MEDICALLY NECESSARY** for the treatment of severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies.

Balloon kyphoplasty or mechanical vertebral augmentation with an FDA cleared device are considered **INVESTIGATIONAL** for all other indications, including use in acute vertebral fractures due to osteoporosis or trauma.

Radiofrequency kyphoplasty is considered **INVESTIGATIONAL**.

Mechanical vertebral augmentation using any other device is considered **INVESTIGATIONAL**.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is required .
Commercial PPO	Prior authorization is required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria **MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO and Indemnity:**

CPT Codes

CPT codes:	Code Description
22513	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; thoracic
22514	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; lumbar
22515	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)

HCPCS Codes:

HCPCS codes:	Code Description
C1062	Intravertebral body fracture augmentation with implant (e.g., metal, polymer)

ICD-10 Procedure Codes

ICD-10-PCS procedure codes:	Code Description
0PU33JZ	Supplement Cervical Vertebra with Synthetic Substitute, Percutaneous Approach
0PU34JZ	Supplement Cervical Vertebra with Synthetic Substitute, Percutaneous Endoscopic Approach

0PU43JZ	Supplement Thoracic Vertebra with Synthetic Substitute, Percutaneous Approach
0PU44JZ	Supplement Thoracic Vertebra with Synthetic Substitute, Percutaneous Endoscopic Approach
0QU03JZ	Supplement Lumbar Vertebra with Synthetic Substitute, Percutaneous Approach
0QU04JZ	Supplement Lumbar Vertebra with Synthetic Substitute, Percutaneous Endoscopic Approach
0QU13JZ	Supplement Sacrum with Synthetic Substitute, Percutaneous Approach

Description

Osteoporotic Vertebral Compression Fracture

Osteoporotic compression fractures are common. It is estimated that up to 50% of women and 25% of men will have a vertebral fracture at some point in their lives. However, only about one-third of vertebral fractures reach clinical diagnosis, and most symptomatic fractures will heal within a few weeks or one month. A minority of individuals will exhibit chronic pain following osteoporotic compression fracture that presents challenges for medical management.

Treatment

Chronic symptoms do not tend to respond to the management strategies for acute pain such as bedrest, immobilization or bracing device, and analgesic medication, sometimes including narcotic analgesics. The source of chronic pain after vertebral compression fracture may not be from the vertebra itself but may be predominantly related to strain on muscles and ligaments secondary to kyphosis. This type of pain frequently is not improved with analgesics and may be better addressed through exercise. Conventional vertebroplasty surgical intervention may be required in severe cases not responsive to conservative measures.

Osteolytic Vertebral Body Fractures

Vertebral body fractures can also be pathologic, due to osteolytic lesions, most commonly from metastatic tumors. Metastatic malignant disease involving the spine generally involves the vertebral bodies, with pain being the most frequent complaint.

Treatment

While radiotherapy and chemotherapy are frequently effective in reducing tumor burden and associated symptoms, pain relief may be delayed days to weeks, depending on tumor response. Further, these approaches rely on bone remodeling to regain vertebral body strength, which may necessitate supportive bracing to minimize the risk of vertebral body collapse during healing.

Summary

Percutaneous balloon kyphoplasty, radiofrequency kyphoplasty, and mechanical vertebral augmentation are interventional techniques involving the fluoroscopically guided injection of polymethyl methacrylate into a cavity created in the vertebral body with a balloon or mechanical device. These techniques have been investigated as options to provide mechanical support and symptomatic relief in patients with osteoporotic vertebral compression fracture or those with osteolytic lesions of the spine (ie, multiple myeloma, metastatic malignancies).

For individuals who have osteoporotic vertebral compression fracture who receive balloon kyphoplasty, or mechanical vertebral augmentation, the evidence includes an Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review, randomized controlled trials (RCTs), and meta-analyses. Relevant outcomes include symptoms, functional outcomes, quality of life, hospitalizations, and treatment-related morbidity. The AHRQ review concluded that vertebroplasty was probably more effective at reducing pain and improving function in patients >65 years of age, but benefits were small. Kyphoplasty was found to be probably more effective than usual care for pain and function in older patients with vertebral compression fracture at up to 1 month and may be more effective at >1 month to ≥1 year but has not been compared against sham therapy. A meta-analysis and moderately sized unblinded RCT have compared kyphoplasty with conservative care and found short-term benefits in pain and other outcomes. One systematic review of RCTs found no significant difference in subsequent fracture between

vertebroplasty and conservative treatment, and another systematic review of prospective and retrospective studies reported improved mortality with either vertebroplasty or balloon kyphoplasty compared with conservative treatment. Other RCTs, summarized in a meta-analysis, have reported similar outcomes for kyphoplasty and vertebroplasty. Three randomized trials that compared mechanical vertebral augmentation (Kiva or SpineJack) with kyphoplasty have reported similar outcomes for both procedures. A major limitation of all these RCTs is the lack of a sham procedure. Due to the possible sham effect observed in the recent trials of vertebroplasty, the validity of the results from non-sham-controlled trials is unclear. Therefore, whether these improvements represent a true treatment effect is uncertain. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have osteolytic vertebral compression fracture who receive balloon kyphoplasty or mechanical vertebral augmentation, the evidence includes RCTs, case series, and systematic reviews of these studies. Relevant outcomes include symptoms, functional outcomes, quality of life, hospitalizations, and treatment-related morbidity. Two RCTs have compared balloon kyphoplasty with conservative management, and another has compared Kiva with balloon kyphoplasty. Results of these trials, along with case series, would suggest a reduction in pain, disability, and analgesic use in patients with cancer-related compression fractures. However, because the results of the comparative studies of vertebroplasty have suggested possible placebo or natural history effects, the evidence these studies provide is insufficient to warrant conclusions about the effect of kyphoplasty on health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have osteoporotic or osteolytic vertebral compression fracture who receive radiofrequency kyphoplasty, the evidence includes a systematic review and an RCT. Relevant outcomes include symptoms, functional outcomes, quality of life, hospitalizations, and treatment-related morbidity. The only RCT (N=80) identified showed similar results between radiofrequency kyphoplasty and balloon kyphoplasty in pain relief, but the review itself was limited by the inclusion of a small number of studies as well as possible bias. Corroboration of these results in a larger number of patients would be needed to determine with greater certainty whether radiofrequency kyphoplasty provides outcomes similar to balloon kyphoplasty. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
6/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
6/2022	Prior authorization information clarified for PPO plans. Effective 6/1/2022
5/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference. Clarified coding information.
6/2020	Annual policy review. Policy statements clarified that the medically necessary statements on compression fractures apply to the thoracolumbar spine. The tradename "Kiva" was removed from policy statements.
9/2019	Policy reformatted into separate statements for balloon kyphoplasty and mechanical vertebral augmentation using Kiva.
5/2019	Annual policy review. Description, summary and references updated. Policy statements unchanged.
6/2018	Annual policy review. Policy statements clarified; intent of statements unchanged.
1/2018	Annual policy review. New investigational indications described. Radiofrequency kyphoplasty added to title. Clarified coding information. Effective 1/1/2018.

1/2017	Annual policy review. Investigational policy statement clarified to delete the wording, "including but not limited to vertebral body stenting." New references added.
9/2015	Annual policy review. New medically necessary indications described. Effective 9/1/2015.
1/2015	Clarified coding information.
9/2014	Annual policy review. New investigational indications described. Effective 9/1/2014.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.
10/2013	Annual policy review. New investigational indications described. Effective 10/1/2013.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
1/2012	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
12/2011	Annual policy review. Changes to policy statements.
1/2011	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
7/2010	Reviewed - Medical Policy Group - Orthopedics, Rehabilitation Medicine and Rheumatology. No changes to policy statements.
6/2010	Annual policy review. Changes to policy statements.
1/2010	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
7/2009	Reviewed - Medical Policy Group - Orthopedics, Rehabilitation Medicine and Rheumatology. No changes to policy statements.
6/2009	New policy, effective 6/1/2009, describing covered and non-covered indications.
11/2008	Annual policy review. No changes to policy statements.
7/2008	Reviewed - Medical Policy Group - Orthopedics, Rehabilitation Medicine and Rheumatology. No changes to policy statements.
1/2008	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
1/2007	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Jarvik JG, Deyo RA. Cementing the evidence: time for a randomized trial of vertebroplasty. *AJNR Am J Neuroradiol.* Sep 2000; 21(8): 1373-4. PMID 11003266
2. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. *Ann Intern Med.* Mar 19 2002; 136(6): 471-6. PMID 11900500
3. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *N Engl J Med.* May 24 2001; 344(21): 1594-602. PMID 11372012
4. Vase L, Riley JL, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. *Pain.* Oct 2002; 99(3): 443-452. PMID 12406519
5. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. *N Engl J Med.* Aug 06 2009; 361(6): 557-68. PMID 19657121
6. Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. *N Engl J Med.* Aug 06 2009; 361(6): 569-79. PMID 19657122

7. Chou R, Fu R, Dana T, et al. Interventional treatments for acute and chronic pain: systematic review [Internet]. AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality; 2021 Sep. Report No.: 21-EHC030
8. Zhao S, Xu CY, Zhu AR, et al. Comparison of the efficacy and safety of 3 treatments for patients with osteoporotic vertebral compression fractures: A network meta-analysis. *Medicine (Baltimore)*. Jun 2017; 96(26): e7328. PMID 28658144
9. Hinde K, Maingard J, Hirsch JA, et al. Mortality Outcomes of Vertebral Augmentation (Vertebroplasty and/or Balloon Kyphoplasty) for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis. *Radiology*. Apr 2020; 295(1): 96-103. PMID 32068503
10. Sun HB, Jing XS, Tang H, et al. Clinical and radiological subsequent fractures after vertebral augmentation for treating osteoporotic vertebral compression fractures: a meta-analysis. *Eur Spine J*. Oct 2020; 29(10): 2576-2590. PMID 32776263
11. Halvachizadeh S, Stalder AL, Bellut D, et al. Systematic Review and Meta-Analysis of 3 Treatment Arms for Vertebral Compression Fractures: A Comparison of Improvement in Pain, Adjacent-Level Fractures, and Quality of Life Between Vertebroplasty, Kyphoplasty, and Nonoperative Management. *JBJS Rev*. Oct 25 2021; 9(10). PMID 34695056
12. Edidin AA, Ong KL, Lau E, et al. Mortality risk for operated and nonoperated vertebral fracture patients in the medicare population. *J Bone Miner Res*. Jul 2011; 26(7): 1617-26. PMID 21308780
13. Ong KL, Beall DP, Frohbergh M, et al. Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty "sham" trials?. *Osteoporos Int*. Feb 2018; 29(2): 375-383. PMID 29063215
14. Wardlaw D, Cummings SR, Van Meirhaeghe J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. *Lancet*. Mar 21 2009; 373(9668): 1016-24. PMID 19246088
15. Boonen S, Van Meirhaeghe J, Bastian L, et al. Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. *J Bone Miner Res*. Jul 2011; 26(7): 1627-37. PMID 21337428
16. Van Meirhaeghe J, Bastian L, Boonen S, et al. A randomized trial of balloon kyphoplasty and nonsurgical management for treating acute vertebral compression fractures: vertebral body kyphosis correction and surgical parameters. *Spine (Phila Pa 1976)*. May 20 2013; 38(12): 971-83. PMID 23446769
17. Tutton SM, Pflugmacher R, Davidian M, et al. KAST Study: The Kiva System As a Vertebral Augmentation Treatment-A Safety and Effectiveness Trial: A Randomized, Noninferiority Trial Comparing the Kiva System With Balloon Kyphoplasty in Treatment of Osteoporotic Vertebral Compression Fractures. *Spine (Phila Pa 1976)*. Jun 15 2015; 40(12): 865-75. PMID 25822543
18. Korovessis P, Vardakastanis K, Repantis T, et al. Balloon kyphoplasty versus KIVA vertebral augmentation--comparison of 2 techniques for osteoporotic vertebral body fractures: a prospective randomized study. *Spine (Phila Pa 1976)*. Feb 15 2013; 38(4): 292-9. PMID 23407406
19. Noriega D, Marcia S, Theumann N, et al. A prospective, international, randomized, noninferiority study comparing an implantable titanium vertebral augmentation device versus balloon kyphoplasty in the reduction of vertebral compression fractures (SAKOS study). *Spine J*. Nov 2019; 19(11): 1782-1795. PMID 31325625
20. Pron G, Holubowich C, Kaulback K. Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic Review. *Ont Health Technol Assess Ser*. 2016; 16(11): 1-202. PMID 27298655
21. Mattie R, Brar N, Tram JT, et al. Vertebral Augmentation of Cancer-Related Spinal Compression Fractures: A Systematic Review and Meta-Analysis. *Spine (Phila Pa 1976)*. Dec 15 2021; 46(24): 1729-1737. PMID 33958537
22. Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. *Lancet Oncol*. Mar 2011; 12(3): 225-35. PMID 21333599
23. Korovessis P, Vardakastanis K, Vitsas V, et al. Is Kiva implant advantageous to balloon kyphoplasty in treating osteolytic metastasis to the spine? Comparison of 2 percutaneous minimal invasive spine techniques: a prospective randomized controlled short-term study. *Spine (Phila Pa 1976)*. Feb 15 2014; 39(4): E231-9. PMID 24253785

24. Feng L, Shen JM, Feng C, et al. Comparison of radiofrequency kyphoplasty (RFK) and balloon kyphoplasty (BKP) in the treatment of vertebral compression fractures: A meta-analysis. *Medicine (Baltimore)*. Jun 2017; 96(25): e7150. PMID 28640091
25. Petersen A, Hartwig E, Koch EM, et al. Clinical comparison of postoperative results of balloon kyphoplasty (BKP) versus radiofrequency-targeted vertebral augmentation (RF-TVA): a prospective clinical study. *Eur J Orthop Surg Traumatol*. Jan 2016; 26(1): 67-75. PMID 26482590
26. Yi X, Lu H, Tian F, et al. Recompression in new levels after percutaneous vertebroplasty and kyphoplasty compared with conservative treatment. *Arch Orthop Trauma Surg*. Jan 2014; 134(1): 21-30. PMID 24287674
27. Baerlocher MO, Saad WE, Dariushnia S, et al. Quality improvement guidelines for percutaneous vertebroplasty. *J Vasc Interv Radiol*. Feb 2014; 25(2): 165-70. PMID 24238815
28. ACR-ASNR-ASSR-SIR-SNIS Practice Parameter for the Performance of Vertebral Augmentation. Available at <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/VertebralAug.pdf>. Accessed February 16, 2022.
29. American Academy of Orthopaedic Surgeons (AAOS). The treatment of symptomatic osteoporotic spinal compression fractures: Summary of Recommendations. 2010; <https://www.maine-general.org/app/files/public/921/aaossummary.pdf>. Accessed February 16, 2022.
30. National Institute for Health and Care Excellence (NICE). Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures [TA279]. 2013; <https://www.nice.org.uk/guidance/ta279>. Accessed February 16, 2022.
31. National Institute for Health and Care Excellence (NICE). Metastatic spinal cord compression in adults: risk assessment, diagnosis and management [CG75]. 2008; <https://www.nice.org.uk/guidance/cg75/chapter/1-Guidance>. Accessed February 16, 2022.